ViennaLab Diagnostics GmbH

Investigate the CYP2C9 metabolizer status and individualize coumarin anticoagulation therapy.

Genetic variants of the drug-metabolizing enzyme CYP2C9 lead to high inter-individual dose response variability of certain drugs, in particular coumarin-based anticoagulants. The CYP2C9 mpx RealFast™ Assay allows for the simultaneous detection of CYP2C9*2 and CYP2C9*3 variants exhibiting impaired enzyme function.

 

CYP2C9

 

  • Both variants of the CYP2C9 enzyme, *2 (c.430C>T) and *3 (c.1075A>C), exhibit impaired function leading to poor metabolism (PM) phenotypes for various drugs.
  • Patients with low enzyme activity are at risk of adverse drug reactions or therapeutic failure, particularly for CYP2C9 substrates with a narrow therapeutic window, such as coumarin-based anticoagulants or phenytoin.
  • Individuals with PM phenotype (i.e. genotypes with homozygous or compound heterozygous *2 or *3 alleles) are at greater risk of severe bleeding during coumarin-based anticoagulation therapy with warfarin, acenocoumarol and – to a lesser extent – phenprocoumon.

 

ProductReg. Stat.REFUnit SizeIFUBrochure
CYP2C9 mpx RealFast™ Assay CE/IVD7-225
7-228
100 rxn
32 rxn

PDF

We use Matomo to analyze the access to our website. We pass on information about your use of our website to our partners for analysis. Our partners may combine this information with other data that you have provided to them or that they have collected as part of your use of the services. I agree.

Deny